Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Author index

Page Path
HOME > Browse articles > Author index
Search
Sei-Hyun Ahn 4 Articles
A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer
Sae Byul Lee, Junetae Kim, Guiyun Sohn, Jisun Kim, Il Yong Chung, Hee Jeong Kim, Beom Seok Ko, Byung Ho Son, Sei-Hyun Ahn, Jong Won Lee, Kyung Hae Jung
Cancer Res Treat. 2019;51(3):1073-1085.   Published online November 1, 2018
DOI: https://doi.org/10.4143/crt.2018.357
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This preliminary study was conducted to evaluate the association between Oncotype DX (ODX) recurrence score and traditional prognostic factors. We also developed a nomogram to predict subgroups with low ODX recurrence scores (less than 25) and to avoid additional chemotherapy treatments for those patients.
Materials and Methods
Clinicopathological and immunohistochemical variables were retrospectively retrieved and analyzed from a series of 485 T1-3N0-1miM0 hormone receptor-positive, human epidermal growth factor 2‒negative breast cancer patients with available ODX test results at Asan Medical Center from 2010 to 2016. One hundred twenty-seven patients (26%) had positive axillary lymph node micrometastases, and 408 (84%) had ODX recurrence scores of ≤25. Logistic regression was performed to build a nomogram for predicting a low-risk subgroup of the ODX assay.
Results
Multivariate analysis revealed that estrogen receptor (ER) score, progesterone receptor (PR) score, histologic grade, lymphovascular invasion (LVI), and Ki-67 had a statistically significant association with the low-risk subgroup. With these variables, we developed a nomogram to predict the low-risk subgroup with ODX recurrence scores of ≤25. The area under the receiver operating characteristic curve was 0.90 (95% confidence interval [CI], 0.85 to 0.96). When applied to the validation group the nomogram was accurate with an area under the curve = 0.88 (95% CI, 0.83 to 0.95).
Conclusion
The low ODX recurrence score subgroup can be predicted by a nomogram incorporating five traditional prognostic factors: ER, PR, histologic grade, LVI, and Ki-67. Our nomogram, which predicts a low-risk ODX recurrence score, will be a useful tool to help select patients who may or may not need additional ODX testing.

Citations

Citations to this article as recorded by  
  • A Novel Nomogram for Estimating a High-Risk Result in the EndoPredict® Test for Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Carcinoma
    Víctor Macarrón, Itsaso Losantos-García, Alberto Peláez-García, Laura Yébenes, Alberto Berjón, Laura Frías, Covadonga Martí, Pilar Zamora, José Ignacio Sánchez-Méndez, David Hardisson
    Cancers.2025; 17(2): 273.     CrossRef
  • Nomogram Development for Assessing Oncotype DX Recurrence Scores in Breast Cancer: A Chinese Population Study
    Jiayin Song, Lin Yang, Zhengqi Feng, Liyu Jiang
    Cancer Medicine.2025;[Epub]     CrossRef
  • Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer
    Wei Wang, Wenqian Lei, Ziru Fang, Ruiyuan Jiang, Xiaojia Wang
    BMC Cancer.2024;[Epub]     CrossRef
  • Development and validation of a clinical breast cancer tool for accurate prediction of recurrence
    Asim Dhungana, Augustin Vannier, Fangyuan Zhao, Jincong Q. Freeman, Poornima Saha, Megan Sullivan, Katharine Yao, Elbio M. Flores, Olufunmilayo I. Olopade, Alexander T. Pearson, Dezheng Huo, Frederick M. Howard
    npj Breast Cancer.2024;[Epub]     CrossRef
  • Prediction of Oncotype DX Recurrence Score Based on Systematic Evaluation of Ki-67 Scores in Hormone Receptor-Positive Early Breast Cancer
    Ji Min Kim, Eun Yoon Cho
    Journal of Breast Cancer.2024; 27(3): 201.     CrossRef
  • Development of a nomogram to predict recurrence scores obtained using Oncotype DX in Japanese patients with breast cancer
    Akio Shibata, Nobuko Tamura, Keiichi Kinowaki, Aya Nishikawa, Kiyo Tanaka, Yoko Kobayashi, Takuya Ogura, Yuko Tanabe, Hidetaka Kawabata
    Breast Cancer.2024; 31(6): 1018.     CrossRef
  • Shear-wave elastography-based nomograms predicting 21-gene recurrence score for adjuvant chemotherapy decisions in patients with breast cancer
    Ji Hyun Youk, Eun Ju Son, Joon Jeong, Hye Mi Gweon, Na Lae Eun, Jeong-Ah Kim
    European Journal of Radiology.2023; 158: 110638.     CrossRef
  • Prediction of Oncotype DX Recurrence Score Using Clinicopathological Variables in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
    Min Chong Kim, Sun Young Kwon, Jung Eun Choi, Su Hwan Kang, Young Kyung Bae
    Journal of Breast Cancer.2023; 26(2): 105.     CrossRef
  • Clinicopathological Factors Associated with Oncotype DX Risk Group in Patients with ER+/HER2- Breast Cancer
    Ran Song, Dong-Eun Lee, Eun-Gyeong Lee, Seeyoun Lee, Han-Sung Kang, Jai Hong Han, Keun Seok Lee, Sung Hoon Sim, Heejung Chae, Youngmee Kwon, Jaeyeon Woo, So-Youn Jung
    Cancers.2023; 15(18): 4451.     CrossRef
  • A simplified risk scoring system for predicting high-risk groups in gene expression tests for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, and node-positive breast cancer
    Kwang Hyun Yoon, Suk Jun Lee, Yujin Kim, Jee Hyun Ahn, Jee Ye Kim, Hyung Seok Park, Seung Il Kim, Seho Park
    Annals of Surgical Treatment and Research.2023; 105(6): 360.     CrossRef
  • Deep Learning-Based Pathology Image Analysis Enhances Magee Feature Correlation With Oncotype DX Breast Recurrence Score
    Hongxiao Li, Jigang Wang, Zaibo Li, Melad Dababneh, Fusheng Wang, Peng Zhao, Geoffrey H. Smith, George Teodoro, Meijie Li, Jun Kong, Xiaoxian Li
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • A Novel Surrogate Nomogram Capable of Predicting OncotypeDX Recurrence Score©
    Matthew G. Davey, Amirhossein Jalali, Éanna J. Ryan, Ray P. McLaughlin, Karl J. Sweeney, Michael K. Barry, Carmel M. Malone, Maccon M. Keane, Aoife J. Lowery, Nicola Miller, Michael J. Kerin
    Journal of Personalized Medicine.2022; 12(7): 1117.     CrossRef
  • Use of a supervised machine learning model to predict Oncotype DX risk category in node-positive patients older than 50 years of age
    Austin D. Williams, Kate R. Pawloski, Hannah Y. Wen, Varadan Sevilimedu, Donna Thompson, Monica Morrow, Mahmoud El-Tamer
    Breast Cancer Research and Treatment.2022; 196(3): 565.     CrossRef
  • The Role of Oncotype DX® Recurrence Score in Predicting Axillary Response After Neoadjuvant Chemotherapy in Breast Cancer
    Jaime A. Pardo, Betty Fan, Alessandra Mele, Stephanie Serres, Monica G. Valero, Isha Emhoff, Amulya Alapati, Ted A. James
    Annals of Surgical Oncology.2021; 28(3): 1320.     CrossRef
  • A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50 years of age
    Jing Yu, Jiayi Wu, Ou Huang, Jianrong He, Li Zhu, Weiguo Chen, Yafen Li, Xiaosong Chen, Kunwei Shen
    Journal of Translational Medicine.2021;[Epub]     CrossRef
  • Clinicopathological correlates, oncological impact, and validation of Oncotype DX™ in a European Tertiary Referral Centre
    Matthew G. Davey, Éanna J. Ryan, Sami Abd Elwahab, Jessie A. Elliott, Peter F. McAnena, Karl J. Sweeney, Carmel M. Malone, Ray McLaughlin, Michael K. Barry, Maccon M. Keane, Aoife J. Lowery, Michael J. Kerin
    The Breast Journal.2021; 27(6): 521.     CrossRef
  • Dynamic contrast enhanced-MRI and diffusion-weighted image as predictors of lymphovascular invasion in node-negative invasive breast cancer
    Bo Bae Choi
    World Journal of Surgical Oncology.2021;[Epub]     CrossRef
  • Prognostic value of the 21-gene recurrence score for regional recurrence in patients with estrogen receptor-positive breast cancer
    Minji Koh, Jinhong Jung, Su Ssan Kim, Seung Do Ahn, Eun Kyung Choi, Il Yong Chung, Jong Won Lee, Sung-Bae Kim, Jae Ho Jeong
    Breast Cancer Research and Treatment.2021; 188(3): 583.     CrossRef
  • A nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancer
    Young Joo Lee, Young Sol Hwang, Junetae Kim, Sei-Hyun Ahn, Byung Ho Son, Hee Jeong Kim, Beom Seok Ko, Jisun Kim, Il Yong Chung, Jong Won Lee, Sae Byul Lee
    Scientific Reports.2021;[Epub]     CrossRef
  • Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor–Positive Early Breast Cancer
    Shin Hye Yoo, Tae-Yong Kim, Miso Kim, Kyung-Hun Lee, Eunshin Lee, Han-Byoel Lee, Hyeong-Gon Moon, Wonshik Han, Dong-Young Noh, Sae-Won Han, Tae-You Kim, Seock-Ah Im
    Clinical Breast Cancer.2020; 20(2): 98.     CrossRef
  • Ki‐67 index, progesterone receptor expression, histologic grade and tumor size in predicting breast cancer recurrence risk: A consecutive cohort study
    Yanna Zhang, Yidong Zhou, Feng Mao, Ru Yao, Qiang Sun
    Cancer Communications.2020; 40(4): 181.     CrossRef
  • Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update
    Kimberly H. Allison, M. Elizabeth H. Hammond, Mitchell Dowsett, Shannon E. McKernin, Lisa A. Carey, Patrick L. Fitzgibbons, Daniel F. Hayes, Sunil R. Lakhani, Mariana Chavez-MacGregor, Jane Perlmutter, Charles M. Perou, Meredith M. Regan, David L. Rimm, W
    Archives of Pathology & Laboratory Medicine.2020; 144(5): 545.     CrossRef
  • Oncotype DX Predictive Nomogram for Recurrence Score Output: The Novel System ADAPTED01 Based on Quantitative Immunochemistry Analysis
    Fabio Marazzi, Roberto Barone, Valeria Masiello, Valentina Magri, Antonino Mulè, Angela Santoro, Federica Cacciatori, Luca Boldrini, Gianluca Franceschini, Francesca Moschella, Giuseppe Naso, Silverio Tomao, Maria Antonietta Gambacorta, Giovanna Mantini,
    Clinical Breast Cancer.2020; 20(5): e600.     CrossRef
  • 13,489 View
  • 345 Download
  • 28 Web of Science
  • 23 Crossref
Close layer
A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer
Changhoon Yoo, Sung-Bae Kim, Jin-Hee Ahn, Jeong Eun Kim, Kyung Hae Jung, Gyung-Yub Gong, Byung-Ho Son, Sei-Hyun Ahn, Seung Do Ahn, Hak-Hee Kim, Hee Jung Shin, Woo Kun Kim
Cancer Res Treat. 2015;47(3):406-415.   Published online November 27, 2014
DOI: https://doi.org/10.4143/crt.2014.073
AbstractAbstract PDFPubReaderePub
Purpose
Given the promising activity of capecitabine and vinorelbine in metastatic breast cancer, this randomized phase II trial evaluated the efficacy and safety of this combination as neoadjuvant chemotherapy in breast cancer. Materials and Methods Patients with operable breast cancer (n=75) were randomly assigned to receive either four cycles of adriamycin 60 mg/m2 plus cyclophosphamide 600 mg/m2 every 3 weeks followed by four cycles of docetaxel 75 mg/m2 every 3 weeks (AC-D) or four cycles of capecitabine 2,000 mg/m2 (day 1-14) plus vinorelbine 25 mg/m2 (days 1 and 8) every 3 weeks followed by four cycles of docetaxel 75 mg/m2 (CV-D). The primary endpoint was pathologic complete response (pCR) in the primary breast (ypT0/is). Results Most patients (84%) had locally advanced (n=41) or inflammatory breast cancer (n=22). pCR rates in the primary breast were 15% (95% confidence interval [CI], 7% to 30%) and 11% (95% CI, 4% to 26%) in the AC-D and CV-D groups, respectively. The overall response rates and 5-year progression-free survival rates in the AC-D and CV-D groups were 62% and 64%, and 51.3% (95% CI, 34.6% to 68.0%) and 30.2% (95% CI, 13.3% to 47.1%), respectively. Although both regimens were well tolerated, CV-D showed less frequent grade 3-4 neutropenia and vomiting than AC-D, whereas manageable diarrhea and hand-foot syndrome were more common in the CV-D group. Conclusion CV-D is a feasible and active non-anthracycline–based neoadjuvant chemotherapy regimen for breast cancer.

Citations

Citations to this article as recorded by  
  • Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer
    Siao-Nge Hoon, Peter K H Lau, Alison M White, Max K Bulsara, Patricia D Banks, Andrew D Redfern
    Cochrane Database of Systematic Reviews.2021;[Epub]     CrossRef
  • rApoptin induces apoptosis in human breast cancer cells via phosphorylation of Nur77 and Akt
    Zhenhuan Hou, Jun Mao, Ying Lu, Lianhong Li
    Biochemical and Biophysical Research Communications.2018; 498(1): 221.     CrossRef
  • Neoadjuvant systemic therapy in breast cancer: Challenges and uncertainties
    Mick Van de Wiel, Yanina Dockx, Tim Van den Wyngaert, Sigrid Stroobants, Wiebren A.A. Tjalma, Manon T. Huizing
    European Journal of Obstetrics & Gynecology and Reproductive Biology.2017; 210: 144.     CrossRef
  • Human serum albumin-mediated apoptin delivery suppresses breast cancer cell growth in vitro and in vivo
    Fang Wu, Yizhi Liu, Jian Li, Lei Hou, Fuxi Lei, Shangke Huang, Lu Feng, Xinhan Zhao
    Oncology Letters.2017; 13(2): 579.     CrossRef
  • Capecitabine in Combination with Standard (Neo)Adjuvant Regimens in Early Breast Cancer: Survival Outcome from a Meta-Analysis of Randomized Controlled Trials
    Ze-Chun Zhang, Qi-Ni Xu, Sui-Ling Lin, Xu-Yuan Li, Hemant Kumar Bid
    PLOS ONE.2016; 11(10): e0164663.     CrossRef
  • 12,484 View
  • 102 Download
  • 6 Web of Science
  • 5 Crossref
Close layer
Gemcitabine Single or Combination Chemotherapy in Post Anthracycline and Taxane Salvage Treatment of Metastatic Breast Cancer: Retrospective Analysis of 124 Patients
Min Kyoung Kim, Sung-Bae Kim, Jin Hee Ahn, Soon Im Lee, Sei-Hyun Ahn, Byung Ho Son, Gyungyub Gong, Hak-Hee Kim, Jung-Shin Lee, Yoon-Koo Kang, Woo Kun Kim
Cancer Res Treat. 2006;38(4):206-213.   Published online December 31, 2006
DOI: https://doi.org/10.4143/crt.2006.38.4.206
AbstractAbstract PDFPubReaderePub
Purpose

To evaluate the efficacy of gemcitabine-based chemotherapy, particularly in patients with anthracycline- and taxane-pretreated 2nd-line or greater metastatic breast cancer, and to compare gemcitabine monotherapy (G) with two gemcitabine-based doublets, gemcitabine/vinorelbine (GV) and gemcitabine/capecitabine (GX).

Materials and Methods

Of 124 consecutive patients who progressed after anthracycline- and taxane-containing chemotherapy, 58 received G alone, 38 received GV, and 28 received GX; their outcomes were analyzed retrospectively.

Results

The median number of prior metastatic chemotherapy regimens was 2 (range 0~4). Visceral metastases were observed in 65 patients (51.4%). The overall response rate was 19.3% (21 partial responses). After a median follow-up period of 21.4 months, the overall survival was 7.6 months (95% CI: 5.5~9.6 months) and the median time to progression was 3.1 months (95% CI: 2.0~4.2 months). Compared with monotherapy (G), com - bination therapy with vinorelbine or capecitabine (GV/GX) was associated with a significantly higher response rate (8.2% vs. 28.3%, p=0.008) and a significantly longer median time to progression (2.8 vs. 3.5 months; p=0.028), but overall survival did not differ between the groups (7.4 vs. 8.2 months, respectively; p=0.54). Most of the adverse treatment-related events were mild to moderate in intensity. The most common adverse event was hematologic toxicity. Multivariate analysis showed that poor performance status and a short disease-free interval were independent prognostic factors for impaired overall survival.

Conclusions

The combination of gemcitabine with vinorelbine or capecitabine was an active and well-tolerated treatment option for taxane- and anthracycline-pretreated 2nd-line or greater metastatic breast cancer patients, and gemcitabine-based doublets were more beneficial than gemcitabine monotherapy in alleviating symptoms for these patients.

Citations

Citations to this article as recorded by  
  • A Systematic Review of Vinorelbine for the Treatment of Breast Cancer
    Ying-Chun Xu, Hong-Xia Wang, Lei Tang, Yue Ma, Feng-Chun Zhang
    The Breast Journal.2013; 19(2): 180.     CrossRef
  • 10,062 View
  • 52 Download
  • 1 Crossref
Close layer
Clinical Value of Cyclooxygenase-2 Expression in Human Breast Carcinoma
Jin-Hee Ahn, Sung-Bae Kim, Sei-Hyun Ahn, Gyung-Yub Gong, Myung-Ju Ahn, Yoon-Koo Kang, Jung-Shin Lee, Woo Kun Kim
Cancer Res Treat. 2004;36(3):192-198.   Published online June 30, 2004
DOI: https://doi.org/10.4143/crt.2004.36.3.192
AbstractAbstract PDFPubReaderePub
Purpose

To determine whether COX-2 expression is associated with clinicopathological parameters, including c-erb-B2 overexpression and angiogenesis, and the disease-free survival of patients with operable breast cancer.

Materials and Methods

Paraffin-embedded tissue samples were selected from 205 patients surgically resected for breast cancer, between 1991 and 1997, and followed-up for at least 4 years. Samples were immunohistochemically stained with antibodies to COX-2, c-erb-B2 and CD34.

Results

COX-2 and c-erb-B2 expressions were detected in 118/205 (57.6%) and 58/205 (28.3%) patients, respectively. COX-2 expression was significantly higher in c-erb-B2 positive than c-erb-B2 negative tumors (75.9% vs. 49.7%, p-value 0.001). COX-2 expression was positively correlated with microvessel count (13.3±8.0 vs. 6.6±7.0, p-value 0.050), but not with other clinicopathological characteristics, including tumor size, involved axil lary lymph nodes and estrogen or progesterone receptor status. Although COX-2 expression itself was not a prognostic marker, breast cancer patients with tumors that co-expressed both COX-2 and c-erb-B2 had a poorer 5-year disease-free survival rate than those that did not (60.2% vs. 78.3%, p-value 0.0527).

Conclusion

Our data suggest that COX-2 expression occurs frequently in c-erb-B2 positive breast cancer, and co-expression of COX-2 and c-erb-B2 may be a useful prognostic marker in patients with operable breast cancer.

Citations

Citations to this article as recorded by  
  • The Role of Immunohistochemical Biomarkers as Prognostic Factors by the Use of a Tissue Microarray in Breast Cancer Patients Under 45-years-old
    Eun Seog Kim, Doo Ho Choi, So Young Jin, Dong Wha Lee, Hee Sook Park, Min Hyuk Lee, Jong Ho Won, Yong Ho Kim, Kyu Taek Lee, Sung Yong Kim
    The Journal of the Korean Society for Therapeutic Radiology and Oncology.2008; 26(1): 45.     CrossRef
  • Expression of Cyclooxygenase-2 in Human Breast Cancer: Relationship with HER-2/neu and other Clinicopathological Prognostic Factors
    Eunmi Nam, Soon Nam Lee, Seock-Ah Im, Do-Yeun Kim, Kyoung Eun Lee, Sun Hee Sung
    Cancer Research and Treatment.2005; 37(3): 165.     CrossRef
  • Cyclooxygenase-2: A Potential Target in Human Cancer
    Jong-Ho Won
    Cancer Research and Treatment.2004; 36(3): 161.     CrossRef
  • 9,784 View
  • 43 Download
  • 3 Crossref
Close layer
Cancer Res Treat : Cancer Research and Treatment
© Korean Cancer Association.
Close layer
TOP